CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 12 enrolled
Drug / intervention
nasal delivery of heated and humidified airdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03935932
NCT03935932N/ACompleted
CompareCT.gov

Study of Humidified Air to Improve Mucociliary Clearance (MCC) in COPD

Frank C Sciurba·interventional·Posted May 2, 2019·Updated Jun 8, 2023

In Brief

A clinical study evaluating nasal delivery of heated and humidified air for COPD. Completed, enrolled 12 participants across 1 site.

Detailed Summary

This purpose of this study is to determine whether nasal delivery of heated and humidified air for a period of 4 hours will improve the clearance of mucus from the lungs of patients with chronic obstructive pulmonary disease (COPD). Mucus clearance will be measured using a nuclear medicine imaging procedure called a mucociliary clearance scan. Humidified air (with added oxygen if needed) will be delivered from the Fisher and Paykel myAirvo2 heater/humidifier through an Optiflow nasal cannula.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesUnited States
CollaboratorsFisher and Paykel Healthcare

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedMay 2, 2019
Enrollment StartJul 15, 2019
Primary CompletionFeb 15, 2021
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 7.2 years ago

Interventions

nasal delivery of heated and humidified airdevice

Subjects will receive nasal delivery of heated and humidified air (plus oxygen if needed) at 30 liters/minute from the Fisher and Paykel myAirvo2 heater/humidifier using an Optiflow nasal cannula.